Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis

Avgerinou, Georgia; Tousoulis, Dimitris; Siasos, Gerasimos; Oikonomou, Evangelos; Maniatis, Konstantinos; Papageorgiou, Nikolaos S.; Paraskevopoulos, Theodoros; Miliou, Antigoni; Koumaki, Dimitra; Latsios, George; Therianiou, Anastasia; Trikas, Athanasios; Kampoli, Anna–Maria; Stefanadis, Christodoulos

doi:10.1016/j.ijcard.2011.06.112

Cited by 50 publications

(45 citation statements)

References 13 publications

(13 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Multiple other studies have demonstrated that anti-TNF-α agents improve FMD in RA patients who are refractory to conventional disease modifying anti-rheumatic drugs (DMARD) therapy [112,113,114,115,116,117]. Anti-TNF-α agents also improve endothelium-dependent vasodilation in patients with spondyloarthritis [118,119], cutaneous psoriasis [72,120] and IBD [121], although studies are small and few. Improvement in endothelial function with anti-TNF-α therapy may correlate with improvement in disease activity and markers of systemic inflammation [122].…”

Section: Effects Of Pharmacologic Interventions On Endothelial Funmentioning

confidence: 99%

“…Gonzalez-Gay and colleagues found reductions only in soluble ICAM-3 and P-selectin after infliximab infusions for patients with RA [131]. Adalimumab therapy in patients with psoriasis has been shown to reduce ICAM-1 levels without affecting other CAMs [120]. These findings are similar to results from studies examining levels of CAMs at baseline across various inflammatory diseases: it has been difficult to discern a consistent profile of CAM expression prior to or in response to disease-modifying therapy.…”

Section: Effects Of Pharmacologic Interventions On Endothelial Funmentioning

confidence: 99%

See 1 more Smart Citation

Endothelial Dysfunction in Chronic Inflammatory Diseases

Steyers

Miller

2014

IJMS

364

299

View full text Add to dashboard Cite

Chronic inflammatory diseases are associated with accelerated atherosclerosis and increased risk of cardiovascular diseases (CVD). As the pathogenesis of atherosclerosis is increasingly recognized as an inflammatory process, similarities between atherosclerosis and systemic inflammatory diseases such as rheumatoid arthritis, inflammatory bowel diseases, lupus, psoriasis, spondyloarthritis and others have become a topic of interest. Endothelial dysfunction represents a key step in the initiation and maintenance of atherosclerosis and may serve as a marker for future risk of cardiovascular events. Patients with chronic inflammatory diseases manifest endothelial dysfunction, often early in the course of the disease. Therefore, mechanisms linking systemic inflammatory diseases and atherosclerosis may be best understood at the level of the endothelium. Multiple factors, including circulating inflammatory cytokines, TNF-α (tumor necrosis factor-α), reactive oxygen species, oxidized LDL (low density lipoprotein), autoantibodies and traditional risk factors directly and indirectly activate endothelial cells, leading to impaired vascular relaxation, increased leukocyte adhesion, increased endothelial permeability and generation of a pro-thrombotic state. Pharmacologic agents directed against TNF-α-mediated inflammation may decrease the risk of endothelial dysfunction and cardiovascular disease in these patients. Understanding the precise mechanisms driving endothelial dysfunction in patients with systemic inflammatory diseases may help elucidate the pathogenesis of atherosclerosis in the general population.

show abstract

Section: Effects Of Pharmacologic Interventions On Endothelial Funmentioning

confidence: 99%

Section: Effects Of Pharmacologic Interventions On Endothelial Funmentioning

confidence: 99%

Endothelial Dysfunction in Chronic Inflammatory Diseases

Steyers

Miller

2014

IJMS

364

299

View full text Add to dashboard Cite

show abstract

“…Endothelial function (EF) impairment, an imbalance between vasoconstrictive and vasodilatory factors, is one of the first events in the process of atherosclerosis and is often used as a sensitive marker of it . Indeed, studies have reported impaired EF among patients with psoriasis, although only a few small‐scale series have evaluated the effect of antipsoriatic treatment on EF as a marker of its utility in treating atherosclerosis …”

mentioning

confidence: 99%

Impact of antipsoriatic therapy on endothelial function

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Avgerinou et al 42 avaliaram o efeito do adalimumab na VOP c-f e na DMF, medidas no início do estudo e às 12 semanas, em 14 doentes com psoríase. Os autores verificaram, à 12ª semana, um aumento significativo da DMF nos doentes com psoríase tratados com adalimumab (p = 0,01) mas não encontraram variações significativas na VOP c-f (Tabela 1).…”

Section: Efeito Da Terapêutica Com Inibidores Do Tnf-a No Risco De Dounclassified

“…De facto, existe bastante evidencia do efeito positivo da terapêutica sistémica biológica e não biológica em marcadores analíticos inflamatórios. 42,52,53 Os estudos realizados até ao momento sugerem que os inibidores do TNF-a se associam a melhoria dos marcadores de disfunção endotelial e aterosclerose subclíni-ca, embora seja necessário determinar se estes fármacos conseguem, de uma forma consistente, reduzir ou reverter a disfunção endotelial e retardar a aterosclerose precoce que atinge os doentes com psoríase. Não obstante, é necessário perceber se a diminuição da inflamação e da disfunção endotelial se traduz na redução da morbilidade e mortalidade cardiovasculares.…”

Section: Conclusãounclassified

Psoríase e Doença Cardiovascular: Impacto da Terapêutica com Inibidores do TNF-alfa

Andrade

Ferreira

Torres

2018

SPDV

View full text Add to dashboard Cite

RESUMO -A psoríase é uma doença inflamatória crónica que atinge 2 a 3% da população. Vários estudos têm demonstrado que a psoríase se associa a um aumento de risco de doença cardiovascular devido ao aumento da prevalência de fatores de risco cardiovasculares tradicionais, e à inflamação sistémica crónica que promove o desenvolvimento de disfunção endotelial e aterosclerose prematura. Esta revisão da literatura tem como objetivo avaliar o impacto dos inibidores do fator de necrose tumoral alfa na função endotelial e no risco de doença cardiovascular nos doentes com psoríase moderada a grave. Os estudos realizados até ao momento sugerem que o tratamento da psoríase com estes fármacos se associa a melhoria dos marcadores de disfunção endotelial e aterosclerose subclínica e a diminuição do risco de doença cardiovascular. PALAVRAS-CHAVE -

show abstract

Anti-tumor necrosis factor alpha treatment with adalimumab improves significantly endothelial function and decreases inflammatory process in patients with chronic psoriasis

Cited by 50 publications

References 13 publications

Endothelial Dysfunction in Chronic Inflammatory Diseases

Endothelial Dysfunction in Chronic Inflammatory Diseases

Impact of antipsoriatic therapy on endothelial function

Psoríase e Doença Cardiovascular: Impacto da Terapêutica com Inibidores do TNF-alfa

Contact Info

Product

Resources

About